UFLPA Entity List Adds BGI Genomics and MGI Tech

The UFLPA Entity List now includes three prominent genomics and life science companies based in China. Importers of sequencing instruments, reagents, laboratory consumables, and related components should immediately reassess suppliers, open orders, and in-transit shipments for potential forced labor enforcement exposure.

What the UFLPA Entity List Update Changes

Three Genomics Companies Have Been Added

The Department of Homeland Security, acting as chair of the Forced Labor Enforcement Task Force, has added BGI Genomics Co., Ltd., MGI Tech Co., Ltd., and Shenzhen BGI Technology Co., Ltd. to the UFLPA Entity List. Shenzhen BGI Technology is also known as BGI Group and BGI Holdings.

All three companies are located in Shenzhen, Guangdong Province. The corporate relationships among them make this more than a simple three-name screening update. Shenzhen BGI Technology is the controlling shareholder of BGI Genomics, while MGI Tech is under the control of the same ultimate controlling shareholder. Importers should therefore examine corporate affiliations, manufacturer identities, and supplier declarations rather than screening only the name printed on an invoice.

The additions bring the UFLPA Entity List to 190 entities. All three companies have been placed in the category covering entities that work with the government of the Xinjiang Uyghur Autonomous Region to recruit, transport, transfer, harbor, or receive forced labor or members of persecuted groups outside Xinjiang.

BGI Genomics and Shenzhen BGI Technology have also been added to the category covering entities that source material from Xinjiang or from parties participating in government labor programs, including programs described as poverty alleviation or pairing assistance.

Why the Listing Has Immediate Import Consequences

Goods mined, produced, or manufactured wholly or partly by a listed entity are generally subject to the UFLPA rebuttable presumption. CBP may treat those goods as produced with forced labor and prohibit their entry under 19 U.S.C. 1307 unless the importer satisfies the applicable evidentiary requirements. The analysis can reach components and intermediate production, not merely finished products carrying a listed company’s brand.

Which Importers and Products Face the Greatest Risk

Life Science Supply Chains Require Product-Level Review

The most direct exposure falls on importers of sequencing instruments, genomic testing equipment, reagents, flow cells, laboratory consumables, replacement parts, and related life science products. Distributors, research institutions, diagnostic companies, pharmaceutical businesses, biotechnology firms, and laboratory supply companies may all have relevant purchasing relationships.

Risk is not limited to merchandise directly purchased from one of the three listed companies. A U.S. importer may buy from an unrelated distributor while the underlying instrument, reagent, subassembly, or component originates with a listed entity. Private-label arrangements and regional distribution structures can make the listed producer less visible in ordinary commercial records.

Importers should identify the actual manufacturer for each affected stock-keeping unit and determine whether listed entities participate at any stage of production. This review should include bills of materials, component suppliers, contract manufacturers, related companies, and upstream production facilities. Product descriptions such as laboratory equipment or diagnostic reagent are generally too broad for a defensible UFLPA assessment.

Brokers Need More Than Entry-Level Name Screening

Customs brokers may not receive complete upstream production information in a routine entry packet. Nevertheless, the appearance of a listed entity in commercial invoices, packing lists, manufacturer data, purchase orders, or client-provided supplier files should trigger escalation before filing.

Broker screening procedures should account for BGI Group and BGI Holdings as aliases of Shenzhen BGI Technology. They should also recognize the ownership relationships involving BGI Genomics and MGI Tech. Exact-name matching alone can miss abbreviations, translated names, legacy names, and related-party references.

The importer of record remains responsible for admissibility, but brokers need clear procedures for identifying and communicating UFLPA risk. Engagement letters, client questionnaires, document requests, and escalation protocols should define what happens when a listed entity or related supplier appears in transaction data.

Immediate Compliance Actions for Importers and Brokers

Screen Open and Future Transactions

The first priority is to screen more than the active vendor master. Importers should review suppliers, manufacturers, sub-suppliers, component producers, contract manufacturers, and known affiliates against the updated UFLPA Entity List. Screening should cover aliases and ownership relationships, including the BGI Group and BGI Holdings names.

Open purchase orders should be reviewed before additional payments, production, or shipment. In-transit cargo requires a separate assessment because goods already moving toward the United States may still encounter admissibility scrutiny upon arrival. Importers should determine whether potentially affected merchandise can be held, redirected, or otherwise managed before it enters the CBP process.

Purchase controls should also be updated. New orders involving genomic testing equipment, sequencing platforms, reagents, and related consumables may require additional supplier certifications and production disclosures before approval. Certifications alone are generally insufficient, but they can support a broader due diligence process when backed by verifiable records.

Assemble Traceability Evidence Before a Detention

Importers should not wait for a CBP detention request to begin tracing the supply chain. A defensible file typically requires records connecting the finished article to each relevant production stage. Depending on the product, that may include purchase orders, invoices, bills of materials, production records, shipping documents, payment records, supplier affidavits, facility information, and transportation records.

The file should establish who produced the merchandise, where production occurred, and which entities supplied significant components or materials. Documents should be internally consistent and traceable across quantities, dates, lot numbers, model numbers, and commercial parties.

Compliance teams should distinguish between demonstrating that the UFLPA presumption does not apply and seeking an exception to the presumption. These are different legal and evidentiary paths. Counsel may be appropriate when records reveal a listed entity, unclear upstream sourcing, or potential exposure under 19 U.S.C. 1307.

Building a Sustainable UFLPA Control Framework

Integrate Screening Into Procurement

UFLPA compliance is most effective before purchase commitments are made. Screening only at entry filing can identify a problem after the importer has paid the supplier, incurred freight costs, and lost practical options for changing the transaction.

Procurement systems should require sufficient manufacturer and origin information before a supplier or product is approved. Higher-risk categories can be routed through enhanced due diligence, while compliance teams maintain documented criteria for escalation. Supplier onboarding should capture legal names, trade names, addresses, parent companies, manufacturing sites, and relevant sub-suppliers.

Importers should also define how frequently existing suppliers are rescreened. Event-driven screening is particularly important when government lists change, ownership changes, a supplier adds a new factory, or a product’s bill of materials is modified.

Connect List Screening With Transaction Data

A supplier screening result has limited value if it cannot be connected to actual purchase orders, shipments, and product records. Effective controls link the screened party to the merchandise and its production role. A distributor that passes screening does not resolve the identity of an undisclosed manufacturer.

Compliance teams should retain evidence that screening occurred, including the names searched, aliases considered, date of review, result, and disposition of any potential match. False positives should be resolved through documented analysis rather than informal assumptions.

Customs brokers can reinforce this framework by identifying missing manufacturer information and requesting clarification before filing. However, brokers should avoid representing routine list screening as a complete forced labor review. UFLPA risk can arise from upstream production relationships that are not visible in standard entry data.

Finally, importers should separate admissibility planning from duty recovery. Merchandise detained, excluded, or prohibited from entry is not a sound basis for a duty drawback strategy. The priority should be preventing noncompliant purchasing and establishing admissibility before goods reach the border.

Frequently Asked Questions

What Is the UFLPA Entity List?

The UFLPA Entity List identifies entities connected to specified forced labor activities or Xinjiang-related government labor programs. Goods mined, produced, or manufactured wholly or partly by listed entities are generally subject to a rebuttable presumption that they are prohibited from U.S. entry under 19 U.S.C. 1307.

Which BGI Companies Were Added?

The additions are BGI Genomics Co., Ltd., MGI Tech Co., Ltd., and Shenzhen BGI Technology Co., Ltd. Shenzhen BGI Technology is also known as BGI Group and BGI Holdings. All three are based in Shenzhen, Guangdong Province.

Does the Listing Cover Products Purchased Through Distributors?

Potentially. Purchasing through an unrelated distributor does not remove UFLPA exposure if a listed entity mined, produced, or manufactured the merchandise wholly or partly. Importers should identify the actual producer and relevant component suppliers rather than relying solely on the seller’s identity.

What Happens if CBP Detains an Affected Shipment?

The importer will generally need to respond within CBP’s applicable process and deadlines. The appropriate response depends on whether the importer contends that the presumption does not apply or seeks an exception. Detailed supply chain tracing and consistent transactional evidence are typically essential.

Can Importers Recover Duties Through Drawback on Prohibited Goods?

Duty drawback should not be treated as a solution for merchandise that is detained, excluded, or prohibited from entry. Drawback generally concerns eligible duties paid on imported merchandise followed by a qualifying exportation or destruction. UFLPA compliance should focus on screening and admissibility before purchase and shipment.

Can a Company Request Removal From the UFLPA Entity List?

A listed entity may submit a written removal request to the Forced Labor Enforcement Task Force chair. Removal generally requires a majority vote of member agencies. A removal decision is not appealable, although a new request may be considered if it contains new information.

How Stable Software Can Help

Strengthen Pre-Purchase Screening Controls

The addition of major genomics companies to the UFLPA Entity List demonstrates why trade compliance controls must operate before cargo reaches the border. Importers and customs brokers need repeatable processes for checking suppliers, aliases, related companies, and transaction parties as lists change.

Teams evaluating how software can support this process can explore Stable Software’s denied party screening platform. Earlier screening can help compliance personnel identify transactions requiring additional review before purchase orders are finalized or entries are prepared.

Stable Software also makes DrawbackAI, flat-license duty drawback software that U.S. customs brokers can white-label for importer clients and use to file under their own filer codes. Stable Software charges a flat software license and never takes a percentage of the refund.

Resources